Teva Lonquex gets EMA panel backing for expanded use in children

Jun. 24, 2022 10:28 AM ETTeva Pharmaceutical Industries Limited (TEVA)By: Ravikash, SA News Editor

The European Medicines Agency (<a href='https://seekingalpha.com/symbol/EMA' title='eMagin Corp'>EMA</a>). The stamp and an imprint

Waldemarus/iStock via Getty Images

  • A committee of the European Medicines Agency (EMA) recommended the approval of expanded use of Teva Pharmaceutical's (NYSE:TEVA) Lonquex for children two years of age and older to treat a side effect of chemotherapy.
  • The EMA's Committee for Medicinal Products for Human Use said Lonquex can now be used in adults and in children two years of age and older for reducing the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes).
  • Neutropenia occurs when the body has fewer neutrophils, a type of white blood cell, due to chemotherapy, among other things. Febrile neutropenia is occurrence of fever during a time of significant neutropenia.
  • The European Commission will make a final decision, which generally follows the recommendation of the EMA, whether to approve the drug.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.